Patient Experiences with Genomic Testing for Prostate Cancer

What is it about?

This qualitative study of 20 patients with low-risk prostate cancer managed with active surveillance found that patients had varying needs and preferences for information about genomic testing, with some preferring more detail and others feeling satisfied with their physician's explanations. Some patients were unaware that genomic testing had been conducted, highlighting the importance of adequate communication. Providers should take care to communicate clear and simple messages about genomic testing results, as patients often look to their physicians for interpretation and may conflate genomic testing with germline genetic testing.

Featured Image

Why is it important?

This research is important because it provides insights into patients' experiences with genomic testing and its role in their decision-making for prostate cancer management. Understanding patients' perspectives on genomic testing can help healthcare providers improve communication and counseling, leading to better patient outcomes. Key Takeaways: 1. Patients held favorable views of genomic testing and recognized its role in risk stratification. 2. Direct and concise information about genomic testing is preferred by patients, and they often rely on their healthcare providers for interpretation. 3. Improving information flow is crucial for patients enrolled in active surveillance, and there is a need for guidance on how best to communicate genomic testing results with patients. 4. Patients often conflate genomic testing with germline genetic testing, leading to misperceptions and confusion about their prostate cancer risk. 5. Approximately one-quarter of surveyed urologists also incorrectly reported that gene expression tests measured hereditary cancer risk, highlighting the need for provider education.